Nasdaq: IMNM

Immunome Inc. (IMNM)

Immunome Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker IMNM. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
IMNM
Exchange
Nasdaq
SEC CIK
1472012
Official filings
SEC EDGAR

Research IMNM

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Immunome Inc.'s stock ticker?

Immunome Inc. trades under the ticker symbol IMNM on Nasdaq. Its SEC Central Index Key (CIK) is 1472012.

Where can I read Immunome Inc.'s SEC filings?

The IMNM SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Immunome Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze IMNM's financial statements?

The IMNM Financials page shows Immunome Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does IMNM compare with its peers and the market?

The IMNM Peer Comparison page lines Immunome Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.